In Re: Lantus Direct Purchaser v., 950 F.3d 1

Background

The FDA's "Orange Book" lists patents that claim an FDA-approved drug; listing can enable a patent-holder to trigger an automatic 30-month stay of FDA approval for a competitor after a Paragraph IV certification.
Sanofi originally listed the patent claiming insulin glargine; later, after approving the Lantus SoloSTAR pen sNDA, Sanofi submitted U.S. Patent No. 8,556,864 (the '864 patent) — a patent on a drive mechanism for pen injectors — for Orange Book listing.
The '864 patent does not mention insulin glargine or the SoloSTAR and claims only certain drive-mechanism features, not the pen or a method of using the drug.
Eli Lilly filed a Paragraph IV certification for its Basaglar KwikPen; Sanofi sued within 45 days, triggering the 30-month stay; parties later settled, delaying competition.
Direct purchasers sued under Section 2 of the Sherman Act alleging Sanofi improperly listed the '864 patent to extend monopoly power and inflate prices; the district court dismissed the antitrust claims.
The First Circuit reversed in part: it held the complaint plausibly alleges the '864 listing was improper, that Sanofi may assert a limited good-faith regulatory-compliance defense, and remanded for further proceedings.

Issues

Issue	Plaintiff's Argument	Defendant's Argument	Held
Was listing the '864 patent in the Orange Book proper?	The '864 patent does not claim the drug or a method of using it and thus was not listable.	The SoloSTAR is a "drug product"/"finished dosage form," so patents on its components (drive mechanism) may be listable.	The complaint plausibly alleges the listing was improper: the '864 claims neither insulin glargine nor the SoloSTAR and thus should not have been listed.
Can reasonableness or regulatory-compliance shield Sanofi from antitrust liability?	No strict immunity; plaintiffs contend improper listing can give rise to liability.	Sanofi seeks immunity if its interpretation was objectively reasonable.	Court recognizes a limited affirmative defense: Sanofi may avoid liability if it proves a reasonable, good-faith effort to comply with the regulatory scheme.
Must plaintiff plead that the Orange Book listing materially caused antitrust injury?	The listing materially contributed to delay and inflated prices via the 30-month stay and settlements.	Sanofi argues the listing alone did not cause the antitrust injury.	At the pleading stage, plaintiffs adequately alleged that the listing was a material cause; dismissal on causation ground was not warranted.
Does Noerr-Pennington/sham-litigation immunity apply to the enforcement suits?	Plaintiffs had alleged sham litigation but abandoned those claims on appeal.	Sanofi argued lawsuits were protected petitioning.	Appeals court did not resolve sham-litigation issue here; plaintiffs abandoned that theory on appeal and the district court's earlier ruling on petitioning remains outside this disposition.

Key Cases Cited

Markman v. Westview Instruments, Inc., 517 U.S. 370 (1996) (claims define the scope of a patent holder's rights)
Bell Atl. Corp. v. Twombly, 550 U.S. 544 (2007) (plausibility pleading standard)
Ashcroft v. Iqbal, 556 U.S. 662 (2009) (pleading must state a plausible claim for relief)
United States v. Grinnell Corp., 384 U.S. 563 (1966) (elements of monopolization under Section 2)
MCI Commc'ns Corp. v. Am. Tel. & Tel. Co., 708 F.2d 1081 (7th Cir. 1983) (good-faith regulatory-compliance defense recognized in regulatory contexts)
S. Pac. Commc'ns Co. v. Am. Tel. & Tel. Co., 740 F.2d 980 (D.C. Cir. 1984) (similar regulatory-context defense)
Phonetele, Inc. v. Am. Tel. & Tel. Co., 664 F.2d 716 (9th Cir. 1981) (regulatory-compliance may be an antitrust defense)
Breiding v. Eversource Energy, 939 F.3d 47 (1st Cir. 2019) (standard for reviewing dismissal; treat pleaded facts as true)
United Mine Workers v. Pennington, 381 U.S. 657 (1965) (Noerr-Pennington doctrine foundations)
E. R.R. Presidents Conf. v. Noerr Motor Freight, Inc., 365 U.S. 127 (1961) (petitioning immunity principles)